Petaling Jaya, August 1, 2022 – Novartis Corporation (Malaysia) Sdn Bhd (Novartis Malaysia) has partnered with Institut Jantung Negara (IJN) on the first-ever scientific partnership to help patients improve disease management of ASCVD through better care and transformative therapies.
ASCVD diseases such as coronary heart disease (CHD), stroke, and peripheral arterial disease (PAD) are caused by the buildup of high cholesterol level hardening and narrowing arteries.
In a first of its kind partnership, the collaboration between Novartis Malaysia and IJN encompasses one of the most comprehensive collaboration featuring three key areas of focus which includes:
- Research collaboration aimed to generate data on ASCVD in Malaysia and measure outcomes of ASCVD patients.
- The establishment of a state-of-the-art multi-disciplinary Cardiovascular Risk Reduction Clinic (CRRC) to optimize ASCVD care.
- Establishing IJN as an internationally recognized training center of excellence in ASCVD care.
Mohamed El-Wakil, Country President, Novartis Malaysia, said: “Novartis recognizes that ASCVD is an undeniable global public health issue and the world’s number one killer. The World Health Organization (WHO) estimates that over 15 million people die from ASCVD every year, accounting for 85% of cardiovascular death. While in Malaysia the National Health and Morbidity Survey 2019, reported that non-communicable diseases (NCD) accounted for 71% of premature deaths in Malaysia. Of key concern within NCDs is ASCVD which contributes to 54% of all NCD deaths.”
“Staying true to our purpose of reimagining medicines to improve and extend people’s lives, we learned about our patients’ journey and develop solutions to meet those gaps and needs in cardiovascular care.”
“This pioneering collaboration between Novartis Malaysia and IJN is crucial as it can be a potential game-changer within the ASCVD treatment paradigm. It brings together the expertise and impeccable standards of care by the nation’s premier cardiovascular specialist institution, IJN, together with the comprehensive experience of Novartis in the area of cardiovascular.
The scientific partnership also represents a significant milestone in the long-standing collaboration between Novartis Malaysia and IJN. Past partnerships with IJN include the IJN-Acute Decompensated Heart Failure (ADHF) Registry which was published internationally and the IJN Heart Failure Clinic.
Datuk Dr. Aizai Azan Abdul Rahim, Chief Executive Officer of Institut Jantung Negara, said: “This collaboration is indeed timely as the prevalence of ASCVD is increasing. In addition, the Ministry of Health has just revealed the National Strategic Plan for Non-Communicable Disease (NCD) 2016-2025, aiming to reduce NCD deaths from 20% to 15% by 2025i. We are looking forward to our collaboration with Novartis Malaysia to achieve our goal “What Good Looks Like” in ASCVD care.”
To date, the partnership has already achieved its first milestone with the launch of the Cardiovascular Risk Reduction Clinic (CRRC). The CRRC which is hosted every Monday in IJN, will provide effective and aggressive lipid and CV risk management for patients with CVD and primary lipid disorders in optimizing ASCVD care. It is driven by a systematic management protocol with well pre-defined inclusion criteria and checklist, led by a trained multi-disciplinary team (clinicians, nurses, dieticians, physiotherapists, and pharmacists).